遠大醫藥(00512.HK)與CDH斥1.5億美元進一步認購Grand Pharma SpherePte股份
格隆匯5月4日丨遠大醫藥(00512.HK)公佈,該集團近日與CDH Genetech Limited訂立了認購協議,據此集團與CDH(或其提名人)將會進一步認購Grand Pharma SpherePte. Ltd.(一間現時集團與CDH分別持有49%及51%股本權益的公司)的股份,比例為按照各自於Grand Pharma Sphere的股本權益比例。進一步認購事項的代價為1.5億美元,而集團與CDH(或其提名人)將會分別認購7350萬美元及7650萬美元。集團與CDH(或其提名人)認購Grand Pharma Sphere的股份將於完成日期或之前同時完成。
認購代價可在雙方書面同意的情況下減少,而各訂約方的減少比例均為相同。不管任何情況,於完成進一步認購事項後集團於Grand Pharma Sphere的持股比例均仍為49%。
Grand Pharma Sphere是Sirtex Medical Pty Limited(一間澳洲註冊的全球性生命科學公司,其主要從事銷售、製造及開發SIR-Spheres,該產品為一種肝癌的針對性放射治療方法)的控股公司。認購代價將用作償還Grand Pharma Sphere及其附屬公司的若干銀行借款。
董事會認為Grand PharmaSphere集團的營運將會有美好前景,特別是開發新的市場例如中國。進一步認購事項將可釋放Grand Pharma Sphere 集團的資金壓力及降低其融資成本,使其有更充裕的資金用於新產品的開發及業務拓展。此亦為展示股東對其的支持。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.